[A22-67] Atezolizumab (NSCLC) – Benefit assessment according to § 35a SGB V
Last updated 05.01.2023
Commission awarded on 05.07.2022 by the Federal Joint Committee (G-BA).
Adult patients with completely resected non-small cell lung cancer (NSCLC) at high risk of recurrence after platinum-based chemotherapy whose tumours express PD-L1 in ≥ 50% of the tumour cells and who do not have EGFR mutations or ALK-positive NSCLC; adjuvant treatment
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.